Constitutive activity of the recombinant human 5-hydroxytryptamine "B
INTRODUCTION
Several lines of research have revealed that a number of guanine nucleotide-binding protein-coupled receptors (GPCR) demonstrate constitutive activity in the absence of agonist in their native state, by reconstitution in phospholipid vesicles, in recombinant heterologous receptor-expression systems and in transgenic mice [1] [2] [3] [4] [5] [6] . This led to the concept that GPCR change their conformation spontaneously or by mutation and oscillate between active and inactive receptor conformations [7] . Receptors exist in an equilibrium between both conformations : an inactive conformation that is structurally constrained and unable to bind a G α -protein subunit, and an active conformation that can interact productively with a GTP-bound G α subunit. Certain ligands, termed inverse agonists or negative antagonists, seem capable of driving activated GPCR to the inactive conformation [8] . Negative antagonism is demonstrated when a ligand binds to a receptor that exhibits some basal activity, which is then decreased. If ligand efficacy represents the differential affinity of a ligand for the active and\or the inactive conformation of the receptor, then a zero efficacy, which would be required for a pure neutral antagonist, might be uncommon, because this would require the same ligand to exhibit a similar affinity for both Abbreviations used : CHO, Chinese hamster ovary ; GPCR, guanine-nucleotide-binding protein-coupled receptors ; GR 55562, 3-(3-dimethylaminopropyl)-4-hydroxy-N-(4-pyridin-4-yl phenyl)-benzenamide ; GR 125743, N- [4- [2,3-f ] indole-3,4h-piperidine] ; TM, transmembrane domain. 1 To whom correspondence should be addressed (e-mail peter.pauwels!pierre-fabre.com).
methoxy-3-(4-methyl-piperazin-1-yl)]-3-methyl-4-pyridin-4-yl-ben-
glycine, asparagine, alanine, lysine, phenylalanine, glutamine and arginine) at the 5-HT "B receptor position 313 in the presence of pertussis toxin (100 ng\ml). Consequently, the constitutive 5-HT "B receptor activity can be modulated by the mutation of Thr$"$, and displays a graded range between 11 % and 59 % of maximal 5-HT "B receptor activation by 5-HT. No clear pattern is apparent in the framework of traditionally cited amino acid characteristics (i.e. residue size, charge or hydrophobicity) to explain the observed constitutive activities. The various amino acid substitutions that yielded enhanced activity are unlikely to make similar intramolecular interactions within the 5-HT "B receptor. It is hypothesized that the positioning of the junction between the third intracellular loop and transmembrane domain VI is altered by mutation of Thr$"$ in the BBXXB motif and thereby unmasks G α -protein interaction points.
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receptor states [9] . Numerous drugs previously classified as neutral antagonists might actually act as inverse agonists [9] ; such a reclassification might have pharmacological and therapeutical implications [6] .
A widely accepted model used to describe the activation of GPCR by agonists is the ternary complex model, which accounts for the co-operative interactions between receptor, G-protein and agonist [10] . This model has recently been extended to accommodate the observation that many receptors can activate G-proteins in the absence of agonist and that mutations in different structural domains of the GPCR can enhance the agonist-independent activity [8, 11] . The extended ternary complex model also accounts for the effects of different classes of drug (full agonists, partial agonists, neutral antagonists and inverse agonists) on receptor signalling [12] .
The C-terminal portion of the third intracellular loop has been suggested to be involved in constraining the GPCR in the inactive (G-protein-uncoupled) conformation [13] . Mutagenesis studies of the BBXXB motif (in which B represents a basic residue and X a non-basic residue) in the third intracellular loop of α #A -adrenergic, α "B -adrenergic, 5-hydroxytryptamine #A (5-HT #A ) and 5-HT #C receptors demonstrated constitutively active mutants [13] [14] [15] [16] . Several anti-psychotic drugs displayed inverse agonist activity by inhibiting the constitutive activation of phosphatidylinositol hydrolysis by mutant Cys$## Lys 5-HT #A receptor [15] . Similarly, mianserin and mesulergine displayed inverse agonist activity by decreasing basal levels of phosphatidylinositol hydrolysis stimulated by mutant Ser$"# Lys 5-HT #C receptors [16] in accordance with the observations for native 5-HT #C receptors expressed in NIH 3T3 cells [17] or Sf * cells [18] . Otherwise, constitutively active mutant (Thr$($ Lys) α #A -adrenergic receptors provide apparently opposite results (i.e. positive efficacy) for ligands that have so far been characterized as α # -adrenergic receptor antagonists [19] . The partial agonist activity of classical antagonists has also been reported for constitutively active mutant dopamine D " (Leu#)' Ala [20] ), AT "A angiotensin II (Asn""" Ala [21] ) and m & muscarinic receptors (Phe%&" Pro [22] ). It is conceivable that structural alterations near the ligand-binding pocket might modify the nature of the ligand-receptor interactions, such that some antagonists are capable of stabilizing an active conformation at the new binding interface generated by the mutation.
The present paper reports on constitutively active mutant 5-HT "B receptors. One particular amino acid (Thr$"$) was exchanged in the BBXXB motif (Arg$"!Lys-Ala-Thr-Lys) by each of the natural amino acids. Because the agonist-independent guanosine 5h- 
MATERIALS AND METHODS

Cloning of mutant 5-HT 1B receptors and rat G o α Cys
351
Ile protein
The recombinant human 5-HT "B receptor (RC code : 2.1.5HT.01B, Genbank accession number M89478) was mutated at position Thr$"$ (codon ACC) into the codons for the 19 natural possible amino acids by a modified overlap extension PCR technique [26] . In brief, linearized pCR3.1\human 5-HT "B plasmid was amplified by PCR into two distinct fragments with the use of two primer sets P1s (5h-GCCATGGAGGAACCG-GGTGCTCAG-3h), P1r (5h-CCCTAGGGTCTTNNNGGCTT-TGCGCTCCCT-3h) and P2s (5h-AGGGAGCGCAAACGGN-NNAAGACCCTAGGG-3h), P2r (5h-AAGTCAACTTGTGCA-CTTAAAACG-3h) (mutated codons are shown in bold). Both fragments were fused together in a second PCR step and the fusion product was subsequently amplified by using the primers P1s and P2r as described [26] to generate a full-length human 5-HT "B receptor gene carrying the respective mutation. Each 5-HT "B receptor Thr$"$ mutant was cloned into 50 ng of a mammalian expression vector, pCR3.1. Sequencing was performed on an ABI Prism 310 Genetic analyser by using Big Dye terminator cycle sequencing, confirming the respective mutations in the 5-HT "B receptor nucleotide sequence. The PTX-resistant rat G-protein α subunit gene G o α Cys$&" Ile was cloned by PCR [23] with the use of specific primers [the reverse primer carried the Cys$&" Ile mutation (TGT into ATT)], designed at respectively the start and stop codons of the gene in accordance with the published nucleotide sequence (GenBank accession number M17526).
Cell culture and transfection
The CHO-K1 cell line (ATCC, CCL 61) was cultured in Ham's F12 nutrient mixture supplemented with 10 % (v\v) heatinactivated foetal calf serum. Cells grown to 60-80 % confluency were used for transfection with a Lipofectamine Plus kit. pCR3.1 plasmid (6 µg) containing the wild-type or mutant 5-HT "B receptor gene, or 3 µg of wild-type or mutant 5-HT "B receptor gene and 3 µg of mutant G o α Cys$&" Ile protein gene, was mixed with 10 µl of Lipofectamine Plus reagent in 0.2 ml of Opti-MEM and incubated at room temperature for 15 min. Subsequently, 20 µl of Lipofectamine reagent diluted in 0.2 ml of Opti-MEM was added for 15 min and exposed with 5 ml of Opti-MEM to CHO-K1 cells for 3 h at 37 mC. Thereafter, cells were further incubated with 10 ml of complete growth medium and harvested 48 h after transfection. Treatment with PTX (100 ng\ml) was performed overnight before membranes were prepared.
Membrane preparation and radioligand binding experiments
Membrane preparation steps were performed at 4 mC. Cells were washed twice with PBS and stored at k80 mC. Cells were then scraped mechanically in 10 mM Tris\HCl, pH 7.5, supplemented with 0.1 mM EDTA and centrifuged for 10 min at 45000 g. The pellet was homogenized in the same buffer with a Polytron and recentrifuged. The final pellet was dissolved in 0.5 ml of Tris\ EDTA buffer (25-45 µg\ml protein) and stored at k80 mC until use. Membrane preparations were diluted in 50 mM Tris\HCl, pH 7.7, containing 4 mM CaCl # , 10 µM pargyline and 0.1 % ascorbic acid and used for binding experiments with N-[$H][4-methoxy-3-(4-methyl-piperazin-1-yl)]-3-methyl-4-pyridin-4-ylbenzenamide (GR 125743, 1 nM) and 5-[$H]carboxamidotryptamine (1 nM) as described [27, 28] . 5-HT (10 µM) was used to determine non-specific radioligand binding.
[
S]GTP[S] binding responses
Agonist-independent (basal) and agonist-dependent [$&S]GTP[S]
binding responses were performed to membranes as described [29] 
Immunological G o α protein detection
Membrane preparations of CHO-K1 cells containing either the wild-type 5-HT "B or 5-HT "B receptor mutants in the presence of the G o α Cys$&" Ile protein were prepared as described above. Total proteins were separated by SDS\PAGE [12.5 % (w\v) gel], as described [30] . Thereafter the proteins were blotted to a nylon membrane by semi-dry electrotransfer (23 V, 45 min) in 192 mM glycine\20 % (v\v) methanol\25 mM Tris\HCl buffer (pH 8.3). Proteins were probed with a polyclonal antibody raised against a peptide corresponding to residues 18-33 of the rat G o α protein.
The incubation was performed in PBS containing 0.1 % (w\v) Tween 20, 5 % (w\v) dried non-fat milk and the antibody at a dilution of 1 : 1000. Proteins were detected with an anti-rabbit IgG antibody coupled to alkaline phosphatase with the use of a colorimetric reaction [0.12 mM Nitro Blue Tetrazolium chloride monohydrate\0.12 mM 5-bromo-4-chloroindol-3-yl phosphate p-toluidine salt\5 mM MgCl # in 100 mM diethanolamine (pH 9.6)].
Protein content
Membrane protein levels were estimated with a dye-binding assay by using a Bio-Rad kit ; BSA was used as a standard [31] . 
RESULTS
[ 35 S]GTP[S] binding responses by 5-HT 1B receptors
In 
-HT-mediated [$&S]GTP[S] binding response was for most of the 5-HT
"B receptor mutants either unchanged from that of the wild-type 5-HT "B receptor or attenuated by 48-59 % (P 0.05) for the mutants with either a proline, glutamate or aspartate residue ( Figure 2C ). Sumatriptan also behaved as an efficacious agonist, with E max values close to those of 5-HT (results not shown). In contrast, GR 125743 (1 µM) clearly demonstrated properties of a partial agonist ( Figure 2D) ; its maximal effect for the 5-HT "B receptor mutants with an arginine or glutamine residue attained the response mediated by 5-HT at the wild-type 5-HT "B receptor.
S]GTP[S] binding responses by 5-HT 1B receptors on coexpression of the rat G o α protein
Co-expression of the 5-HT "B receptor with a rat G o α protein was investigated to enhance the resolution of constitutive 5-HT "B Table 1 and are compared with their pK i values for the wild-type 5-HT "B receptor. Each 
Figure 2 [ 35 S]GTP[S] binding responses and expression levels of wild-type (wt) 5-HT 1B receptor and 5-HT 1B receptor mutants Thr 313
Xaa in CHO-K1 cells
DISCUSSION
The present paper reports on the modulation of agonist-independent and agonist-dependent activation of the recombinant human 5-HT "B receptor by mutation of Thr$"$ in the BBXXB motif located in the C-terminal portion of the third intracellular loop. Wild-type 5-HT "B receptors yielded a low (less than 10 %) and variable level of constitutive activity in CHO-K1 cells. Mutation of Thr$"$ in the 5-HT "B receptor to either a lysine, an arginine or a glutamine residue increased constitutive activity by 26-41 %, which was reversed by inverse agonists. Increased constitutive receptor activation was provided by co-expression of the 5-HT "B receptor with a PTX-resistant rat G o α Cys$&" Ile protein. The wild-type 5-HT "B receptor displayed a doubling of basal activity, whereas this response was amplified with a series of diverse amino acid substitutions (isoleucine, glycine, asparagine, alanine, lysine, phenylalanine, glutamine and arginine) at 5-HT "B receptor position 313. Enhanced basal activity was maximal (approx. 500 %) with the 5-HT "B receptor mutants Thr$"$ Gln and Thr$"$ Arg ; this activity represented approx. 50 % of maximal receptor activation by 5-HT. Few or no modifications in the 5-HT "B receptor expression levels were observed for the 5-HT "B receptor mutations in either the absence or the presence of the G o α Cys$&" Ile protein, with the exception of the mutant Thr$"$ His. This suggests that the observed effects were caused primarily by changes in receptor-G-protein coupling. Specific 
